Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
Hemlibra (emicizumab) is a bispecific monoclonal antibody that mimics the coagulation function of clotting factor VIII (FVIII). This “nonfactor” therapy bridges activated clotting factors IX and X, thereby fulfilling the role normally played by activated FVIII in the coagulation cascade.
Nuzyra (omadacycline) is an oral and intravenous aminomethylcycline antibiotic for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. It is designed to surmount certain forms of antibiotic resistance found in community-acquired infections.
Inotersen is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.
Libtayo (cemiplimab) is an intravenous programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Epidiolex is an oral liquid formulation of a highly purified extract of cannabidiol (CBD). CBD is a non-psychoactive component of Cannabis sativa (marijuana). It is approved by the Food and Drug Administration for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years of age and older.